Skip to content
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies episode artwork

Apr 17, 2024 35 min

Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

from The Bio Report Hosted by Levine Media Group

Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s technology platform is seeking to change the immunotherapy landscape with new treatments that are better targeted, more potent, and less toxic. We spoke to Don Wyatt, chief business officer for HighField Biopharmaceuticals, about the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

Episode details come from the podcast's RSS feed.

Embed this episode

Don Wyatt, chief business officer for Highfield Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

Ready to play

Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

0:00 35:04

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Bio Report?

This episode is 35 minutes long.

When was this The Bio Report episode published?

This episode was published on April 17, 2024.

Can I download this The Bio Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.